Jan 29 (Reuters) - Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.1 USD | -2.11% | -3.52% | +32.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.72% | 12.37B | |
+7.69% | 115B | |
+12.72% | 107B | |
-13.24% | 22.31B | |
-3.99% | 21.6B | |
-6.35% | 18.23B | |
-39.93% | 17.62B | |
+6.75% | 14.26B | |
-28.62% | 8.28B | |
+17.87% | 8.26B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta says its experimental Duchenne drug more effective than older medicine